Christine Zedelmayer Net Worth

The estimated Net Worth of Christine Zedelmayer is at least $94.3 mil dollars as of 16 November 2021. Ms. Zedelmayer owns over 23,334 units of Equillium Inc stock worth over $94,338 and over the last 5 years she sold EQ stock worth over $0. In addition, she makes $0 as Chief Operating Officer e Senior Vice President at Equillium Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Zedelmayer EQ stock SEC Form 4 insiders trading

Christine has made over 1 trades of the Equillium Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently she exercised 23,334 units of EQ stock worth $57,168 on 16 November 2021.

The largest trade she's ever made was exercising 23,334 units of Equillium Inc stock on 16 November 2021 worth over $57,168. On average, Christine trades about 2,593 units every 0 days since 2020. As of 16 November 2021 she still owns at least 109,759 units of Equillium Inc stock.

You can see the complete history of Ms. Zedelmayer stock trades at the bottom of the page.

Christine Zedelmayer biography

Christine Zedelmayer serves as Chief Operating Officer, Senior Vice President of the Company. Ms. Zedelmayer served as our Vice President of Operations from February 2018 through December 2019. Prior to Equillium, Ms. Zedelmayer was owner and principal consultant at Centerra Consulting, LLC, a project management and investor relations consulting firm focused on life sciences, from 2012 to February 2018, where she led strategic business development projects for clients and served as head of investor relations for a variety of medical device companies. Prior to Centerra, from 2003 to 2012, Ms. Zedelmayer held a variety of roles at Amylin Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, including Senior Director of Alliance Management, where she led the global collaboration with Eli Lilly and as Executive Director of Investor Relations. Before joining Amylin, Ms. Zedelmayer held various leadership positions within project management at Amgen Inc., a publicly-held biopharmaceutical company, Ligand Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, and Hybritech, Inc., a privately-held medical diagnostics company. Ms. Zedelmayer received her B.S. in Electrical Engineering at San Diego State University and a M.B.A. with Finance emphasis at California Lutheran University.

How old is Christine Zedelmayer?

Christine Zedelmayer is 50, she's been the Chief Operating Officer e Senior Vice President of Equillium Inc since 2020. There are 9 older and 6 younger executives at Equillium Inc. The oldest executive at Equillium Inc is Bala Manian, 74, who is the Independent Director.

What's Christine Zedelmayer's mailing address?

Christine's mailing address filed with the SEC is 2223 AVENIDA DE LA PLAYA, SUITE 105, , LA JOLLA, CA, 92037.

Insiders trading at Equillium Inc

Over the last 6 years, insiders at Equillium Inc have traded over $2,616,040 worth of Equillium Inc stock. The most active insiders traders include Daniel Bradbury, Mark Pruzanski, eStephen Connelly. On average, Equillium Inc executives and independent directors trade stock every 95 days with the average trade being worth of $20,757. The most recent stock trade was executed by Jason A Keyes on 16 July 2024, trading 10,000 units of EQ stock currently worth $8,700.

What does Equillium Inc do?

equillium, inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor cd6, which is in phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and phase 1 clinical trial for the treatment of asthma and lupus nephritis. the company was formerly known as attenuate biopharmaceuticals, inc. and changed its name to equillium, inc. in may 2017. equillium, inc. was founded in 2017 and is headquartered in la jolla, california.

Complete history of Ms. Zedelmayer stock trades at Equillium Inc

Equillium Inc executives and stock owners

Equillium Inc executives and other stock owners filed with the SEC include:

• Krishna Polu,
  Executive Vice President - Research and Development, Chief Medical Officer
• Bruce Steel,
  President, Chief Executive Officer, Director
• Daniel Bradbury,
  Executive Chairman of the Board
• Dr. Krishna R. Polu,
  Consultant
• Dr. Stephen Connelly Ph.D.,
  Chief Scientific Officer & Director
• Bruce D. Steel C.F.A.,
  Co-Founder, Pres, CEO & Director
• Stephen Connelly,
  Chief Scientific Officer, Director
• Daniel Mark Bradbury,
  Exec. Chairman
• Mark Pruzanski,
  Independent Director
• Charles McDermott,
  Independent Director
• Bala Manian,
  Independent Director
• Martha Demski,
  Independent Director
• Matthew Ritter,
  Vice President - Corporate Development
• Maple Fung,
  Vice President - Clinical Development
• Christine Zedelmayer,
  Chief Operating Officer, Senior Vice President
• Jason Keyes,
  Chief Financial Officer
• Jason A. Keyes,
  Chief Financial Officer
• Dr. Dolca Thomas M.D.,
  Exec. VP of R&D and Chief Medical Officer
• Joel M. Rothman,
  Chief Devel. Officer
• Michael Moore,
  VP of Investor Relations & Corp. Communications
• Christine Zedelmayer M.B.A., P.M.P.,
  Sr. VP & COO
• Yu (Katherine) Xu,
  
• Sa Biocon,
  10% owner
• Dolca Thomas,
  Chief Medical Officer
• Joel Rothman,
  Chief Development Officer
• Barbara Troupin,